NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS

Subcutaneous daratumumab (Darzalex Faspro) significantly reduced disease progression or death risk and improved overall survival in high-risk smoldering multiple myeloma patients, according to the phase 3 AQUILA study. The treatment showed a 51% reduction in progression risk and a 48% reduction in death risk, with a 60-month OS rate of 93% compared to 86.9% with active monitoring. Daratumumab also delayed progression and improved response rates, with manageable safety profiles.

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

Subcutaneous daratumumab significantly improved PFS and OS vs active monitoring in high-risk smoldering multiple myeloma, reducing progression risk by 51% and death risk by 48%.

Dana-Farber Cancer Institute researchers present three studies at the 66th ASH Annual Meeting on early detection and intervention in multiple myeloma. The studies include a genomic-based MM-like score for predicting progression from precursor conditions, identifying M-proteins up to 22 years before diagnosis, and a tool called PANGEA 2.0 improving risk stratification for smoldering multiple myeloma.

Cabazitaxel demonstrated efficacy in mCRPC patients with bone metastases, including those with HRR mutations. Reactive hematopoiesis correlated with improved survival, suggesting bone biomarkers as predictors of cabazitaxel efficacy.

Huawei's TECH4ALL initiative showcased its role in Europe's digital and green transformation at Huawei Connect Paris 2024, highlighting projects like Tech4Nature and forest fire prevention systems. Partnerships with IUCN, UNESCO, and others drive sustainable development and digital inclusion.

ANGLE plc announced research findings on dual analysis of CTCs and ctDNA in NSCLC patients, showing complementary information for better resistance mutation and DNA methylation identification.

Tenecteplase, an off-label clot-busting drug, shows slightly better outcomes for stroke patients compared to alteplase, with higher likelihood of excellent recovery and reduced disability at 3 months, according to a review published in 'Neurology'.

Tenecteplase, compared to alteplase, shows a 5% higher likelihood of excellent recovery and a 10% higher likelihood of reduced disability in ischemic stroke patients, according to a meta-analysis published in 'Neurology'.